Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41571-024-00921-y | DOI Listing |
Publication Analysis
Top Keywords
vimseltinib improves
4
improves outcomes
4
outcomes tenosynovial
4
tenosynovial giant
4
giant cell
4
cell tumour
4
vimseltinib
1
outcomes
1
tenosynovial
1
giant
1
Similar Publications
Article Synopsis
- The MOTION trial aimed to evaluate the effectiveness of vimseltinib in reducing tumors in patients with symptomatic tenosynovial giant cell tumor (TGCT) when surgery wasn’t an option.
- The results indicated that participants treated with vimseltinib showed significant tumor shrinkage (30% or more) and reported improvements in mobility, physical function, and overall health compared to those on a placebo.
- Vimseltinib presents a promising new treatment option for TGCT, offering benefits in tumor reduction and quality of life with manageable side effects.
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
June 2024
Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.
Article Synopsis
- Tenosynovial giant cell tumour (TGCT) is a locally aggressive tumor with limited treatment options, leading this study to assess vimseltinib, a CSF1R inhibitor, in patients whose TGCT symptoms prevent surgery.
- The MOTION trial, a phase 3 randomized study, involved 123 adults from 35 hospitals globally, comparing vimseltinib to a placebo over 24 weeks, focusing on the objective response rate determined by independent radiological review.
- Results showed a significant objective response rate of 40% for vimseltinib compared to 0% for placebo, with most side effects being mild (grade 1 or 2), highlighting vimseltinib's
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!